275 related articles for article (PubMed ID: 29886786)
41. Antitumor Activity of Rivoceranib Against Canine Mammary Gland Tumor Cell Lines.
Lee JH; Li Q; An JH; Chae HK; Choi JW; Kim BJ; Song WJ; Youn HY
Anticancer Res; 2019 Oct; 39(10):5483-5494. PubMed ID: 31570442
[TBL] [Abstract][Full Text] [Related]
42. A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy.
Yang H; Sun S; Mei Z; Xiang Q; Yang C; Chen M; Xie C; Zhou Y; Qiu H
Drug Des Devel Ther; 2021; 15():4665-4674. PubMed ID: 34815663
[TBL] [Abstract][Full Text] [Related]
43. Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis.
Huang Z; Zhao B; Qin Z; Li Y; Wang T; Zhou W; Zheng J; Yang S; Shi Y; Fan Y; Xiang R
Eur J Med Chem; 2019 Nov; 181():111541. PubMed ID: 31382120
[TBL] [Abstract][Full Text] [Related]
44. Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines.
Miyamoto Y; Nakagawa S; Wada-Hiraike O; Seiki T; Tanikawa M; Hiraike H; Sone K; Nagasaka K; Oda K; Kawana K; Nakagawa K; Fujii T; Yano T; Kozuma S; Taketani Y
Oncol Rep; 2013 Jan; 29(1):51-7. PubMed ID: 23064281
[TBL] [Abstract][Full Text] [Related]
45. Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer-bearing mice and patients.
Liu M; Li H; Wang X; Jing L; Jiang P; Li Y
Cancer Med; 2020 Apr; 9(8):2660-2673. PubMed ID: 32073228
[TBL] [Abstract][Full Text] [Related]
46. Apatinib inhibits the growth of small cell lung cancer via a mechanism mediated by VEGF, PI3K/Akt and Ki-67/CD31.
Zhong N; Zhuang W; Huang Q; Wang Q; Jin W
J Cell Mol Med; 2021 Nov; 25(21):10039-10048. PubMed ID: 34590406
[TBL] [Abstract][Full Text] [Related]
47. CKD-602, a topoisomerase I inhibitor, induces apoptosis and cell-cycle arrest and inhibits invasion in cervical cancer.
Lee S; Ho JY; Liu JJ; Lee H; Park JY; Baik M; Ko M; Lee SU; Choi YJ; Hur SY
Mol Med; 2019 May; 25(1):23. PubMed ID: 31138113
[TBL] [Abstract][Full Text] [Related]
48. FOXM1 Contributes to Chemotherapy Sensitivity in Cervical Cancer by Regulating TTK.
Tang Q; Xu A; Yang Y; Zhang Y; Sun J
Discov Med; 2023 Jun; 35(176):208-220. PubMed ID: 37272088
[TBL] [Abstract][Full Text] [Related]
49. The effect of apatinib combined with chemotherapy or targeted therapy on non-small cell lung cancer in vitro and vivo.
Liu M; Wang X; Li H; Xu L; Jing L; Jiang P; Liu B; Li Y
Thorac Cancer; 2019 Oct; 10(10):1868-1878. PubMed ID: 31486270
[TBL] [Abstract][Full Text] [Related]
50. Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice.
Zhou K; Zhang JW; Wang QZ; Liu WY; Liu JL; Yao L; Cai MM; Ni SY; Cai QY; Wang GJ; Zhou F
Acta Pharmacol Sin; 2019 Apr; 40(4):556-562. PubMed ID: 29977004
[TBL] [Abstract][Full Text] [Related]
51. Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients.
Zhang L; Chen L; Yu H
Invest New Drugs; 2020 Aug; 38(4):1186-1191. PubMed ID: 31637668
[TBL] [Abstract][Full Text] [Related]
52. A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells.
Xiong F; Jiang M; Huang Z; Chen M; Chen K; Zhou J; Yin L; Tang Y; Wang M; Ye L; Zhan Z; Duan J; Fu H; Zhang X
Integr Cancer Ther; 2014 Mar; 13(2):152-60. PubMed ID: 24105357
[TBL] [Abstract][Full Text] [Related]
53. Apatinib, a Novel Tyrosine Kinase Inhibitor, Promotes ROS-Dependent Apoptosis and Autophagy via the Nrf2/HO-1 Pathway in Ovarian Cancer Cells.
Sun X; Li J; Li Y; Wang S; Li Q
Oxid Med Cell Longev; 2020; 2020():3145182. PubMed ID: 32509141
[TBL] [Abstract][Full Text] [Related]
54. Anti-tumor effects of rivoceranib against canine melanoma and mammary gland tumour in vitro and in vivo mouse xenograft models.
Li Q; Kim YS; An JH; Kwon JA; Han SH; Song WJ; Youn HY
BMC Vet Res; 2021 Oct; 17(1):338. PubMed ID: 34702279
[TBL] [Abstract][Full Text] [Related]
55. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
56. Growth arrest-specific 5 attenuates cisplatin-induced apoptosis in cervical cancer by regulating STAT3 signaling via miR-21.
Yao T; Lu R; Zhang J; Fang X; Fan L; Huang C; Lin R; Lin Z
J Cell Physiol; 2019 Jun; 234(6):9605-9615. PubMed ID: 30352127
[TBL] [Abstract][Full Text] [Related]
57. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer.
Kang SK; Bae HJ; Kwon WS; Kim TS; Kim KH; Park S; Yu SY; Hwang J; Park J; Chung HC; Rha SY
Cell Oncol (Dordr); 2021 Dec; 44(6):1387-1403. PubMed ID: 34791636
[TBL] [Abstract][Full Text] [Related]
59. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer.
Ma X; Zhang J; Liu S; Huang Y; Chen B; Wang D
Cancer Chemother Pharmacol; 2012 Feb; 69(2):485-94. PubMed ID: 21842204
[TBL] [Abstract][Full Text] [Related]
60. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
